Ken Griffin Ligand Pharmaceuticals Inc Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 12,800 shares of LGND stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,800
Previous 10,800
18.52%
Holding current value
$1.38 Million
Previous $1.08 Million
26.83%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding LGND
# of Institutions
276Shares Held
18.5MCall Options Held
30.8KPut Options Held
5.2K-
Black Rock Inc. New York, NY2.87MShares$310 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.09MShares$225 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.02MShares$110 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C3884KShares$95.6 Million0.11% of portfolio
-
State Street Corp Boston, MA744KShares$80.4 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.82B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...